Merck’s Experimental Hepatitis C Drug Beats Victrelis

Merck & Co. (MRK) said an experimental drug against hepatitis C was more effective than its Victrelis pill in a patient study.

The virus was undetectable in the blood of as many as 92 percent of patients six months after they stopped the 12-week course of treatment with the drug, known as MK-5172, compared with 54 percent of those who received Victrelis, Whitehouse Station, New Jersey-based Merck said in a statement today. The trial included 332 people with the most common form of hepatitis C in the U.S., and all received standard therapy ribavirin in addition to either MK-5172 or Victrelis.

Merck said yesterday that it’s entered a non-exclusive agreement with Bristol-Myers Squibb Co. (BMY) to test MK-5172 in combination with Bristol’s daclatasvir.

“The interim findings from this study provide clear direction for future larger trials designed to evaluate MK-5172 in novel, all-oral regimens for HCV,” Eliav Barr, Merck’s vice president of infectious diseases, said in today’s statement.

Merck rose 1.5 percent to $48.63 at the close in New York.

The drug caused increased levels of potentially harmful liver enzymes in some patients on the highest doses, who had their doses reduced as a result, Merck said.

Victrelis was approved by the U.S. Food and Drug Administration in May 2011, the first hepatitis C drug in almost a decade.

To contact the reporter on this story: Simeon Bennett in Geneva at sbennett9@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.